Sanofi Reports the Selection of IPH6401/SAR’514 in IND-Enabling Studies for Cancer
- Sanofi has chosen to advance IPH6401/SAR'514 (BCMA-targeting NK cell engager) into IND-enabling studies resulting in $3.040M milestones for cancer treatment & provide a more effective therapeutic window than bispecific T lymphocyte-engaging approaches
- In pre-clinical models, IPH6401/SAR'514 demonstrated anti-tumor effectiveness & positive drug characteristics. Sanofi will lead the development, manufacturing & commercialization of IPH6401/SAR’514
- Under the 2016 agreement, Sanofi & Innate collaborated to develop 2 bispecific NK cell engagers using the ANKET platform that targets 2 NK activating receptors i.e., NKp46 & CD16 to optimize NK cell activation & Sanofi’s antibody format & anti-tumor target Abs
Ref: Innate Pharma | Image: Sanofi
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at firstname.lastname@example.org.